Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE PRESERVATIVE FREE versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE PRESERVATIVE FREE versus LUSEDRA.
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3) in the gastrointestinal tract, producing antispasmodic effects by reducing smooth muscle contractions.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
20 mg intramuscularly every 4-6 hours.
5 mg orally once daily.
None Documented
None Documented
5-8 hours; may be prolonged in elderly or patients with hepatic impairment
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal (approximately 50-80% as unchanged drug and metabolites), biliary/fecal (minor, <10%)
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category A/B
Category C
Anticholinergic
Anticholinergic